AU2720600A - Vaccination method for efficient induction of cytotoxic t lymphocyte response - Google Patents

Vaccination method for efficient induction of cytotoxic t lymphocyte response

Info

Publication number
AU2720600A
AU2720600A AU27206/00A AU2720600A AU2720600A AU 2720600 A AU2720600 A AU 2720600A AU 27206/00 A AU27206/00 A AU 27206/00A AU 2720600 A AU2720600 A AU 2720600A AU 2720600 A AU2720600 A AU 2720600A
Authority
AU
Australia
Prior art keywords
epitope
lymphocyte response
cytotoxic
efficient induction
vaccination method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27206/00A
Inventor
Todd M. Allen
Deborah L. Fuller
James T. Fuller
Thorsten U. Vogel
David I. Watkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Wisconsin Alumni Research Foundation
Original Assignee
Powderject Vaccines Inc
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22361181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2720600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Powderject Vaccines Inc, Wisconsin Alumni Research Foundation filed Critical Powderject Vaccines Inc
Publication of AU2720600A publication Critical patent/AU2720600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for inducing an epitope-specific cytotoxic lymphocyte response in primates is disclosed. The method involves delivering a DNA-based vaccine that encodes an MHC class I epitope and a polyepitope and an MHC class I epitope and the hepatitis B core antigen into the primate, followed by delivering a modified virus vaccine that encodes an MHC class I epitope and a polyepitope into the primate.
AU27206/00A 1999-01-08 2000-01-06 Vaccination method for efficient induction of cytotoxic t lymphocyte response Abandoned AU2720600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11540599P 1999-01-08 1999-01-08
US60115405 1999-01-08
PCT/US2000/000286 WO2000040261A2 (en) 1999-01-08 2000-01-06 Vaccination method for efficient induction of cytotoxic t lymphocyte response

Publications (1)

Publication Number Publication Date
AU2720600A true AU2720600A (en) 2000-07-24

Family

ID=22361181

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27206/00A Abandoned AU2720600A (en) 1999-01-08 2000-01-06 Vaccination method for efficient induction of cytotoxic t lymphocyte response

Country Status (5)

Country Link
EP (1) EP1140162B1 (en)
AT (1) ATE274354T1 (en)
AU (1) AU2720600A (en)
DE (1) DE60013242D1 (en)
WO (1) WO2000040261A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
ATE494387T1 (en) 2001-11-07 2011-01-15 Mannkind Corp EXPRESSION VECTORS ENCODING EPITOPES OF ANTIGENS AND METHOD FOR THE CONCEPTION THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction

Also Published As

Publication number Publication date
WO2000040261A2 (en) 2000-07-13
ATE274354T1 (en) 2004-09-15
WO2000040261A3 (en) 2000-11-30
EP1140162B1 (en) 2004-08-25
EP1140162A2 (en) 2001-10-10
DE60013242D1 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2002034205A3 (en) Using heat shock proteins to increase immune response
WO2001091536A3 (en) Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens
AU6616301A (en) Modification of hepatitis b core antigen
DK0584348T3 (en) Genetic vaccine against immunodeficiency viruses
AU1013601A (en) Method of inducing and/or enhancing an immune response to tumor antigens
WO1999002183A3 (en) A method of inducing a ctl response
WO2000000616A3 (en) Marburg virus vaccines
EP1270016A4 (en) Aids virus vaccine with the use of sendai virus vector
HK1048434A1 (en) Influenza vaccine
AP2003002734A0 (en) Purification of HBV antigens for use in vaccines.
WO2004043399A3 (en) Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines
EP1395283A4 (en) Heterologous protection induced by immunization with invaplex vaccine
AU2720600A (en) Vaccination method for efficient induction of cytotoxic t lymphocyte response
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
WO2003103570A3 (en) Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles
GB9818133D0 (en) Vaccine
WO2002095048A3 (en) Methods for genetic immunization
MY141983A (en) Hepatitis b virus surface antigen as a mucosal immunoenhancer, resulting formulations
IL106306A0 (en) Parenteral immunization against rotavirus
IL149415A0 (en) Adjuvanted genetic vaccines
AU2002219290A1 (en) Proteinic antigens inducing antibodies neutralising hiv virus
WO1997034136A3 (en) Methods for detecting antibodies to hav 3c proteinase
EP0972523A3 (en) Method and compositions for inducing immunity to viruses

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase